What This Report Will Provide?

The HCS instruments market accounted for the largest share of HCS market primarily attributed to advances in instrumentation and automation techniques and high prices of the HCS instruments. The software segment is expected to register the highest growth during the forecast period.

The growth of this market is attributed to the technological advancements in image acquisition, data analysis, and storage capabilities and the need to obtain information on changes in cell morphology through high-quality images.

Expected Revenue Growth:

[166 Pages Report] MarketsandMarkets forecasts the high content screening market to grow from USD 557.1 million in 2017 to USD 909.0 million by 2022, at a Compound Annual Growth Rate (OTC:CAGR) of 10.3% during the forecast period.

Major Growth Boosters:

The major factors that are expected to be driving the high content screening market are need for cost containment in pharma R&D, growth in funding for cellular research, and technological advancements in HCS solutions are expected to support the growth of the HCS market during the forecast period.

On the other hand, the high cost of HCS instruments and the dearth of knowledgeable and skilled personnel for the operation of high-content screening instruments are expected to restrain the market growth to a certain extent.

Download PDF Brochure:   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=42710391 

Recent Developments

• In February 2017, Molecular Devices, LLC (U.S.), a subsidiary of Danaher Corporation, launched the SpectraMax iD3 Multi-Mode Microplate Reader, a solution which allows multiple SpectraMax iD3 instruments to be controlled from one workstation using network connectivity. .
• In January 2017, PerkinElmer, Inc. launched the Vectra Polaris automated quantitative pathology imaging system. This multi-modal tissue imaging system enables researchers to gain a deeper level of understanding of disease mechanisms related to new cancer immunotherapy approaches.
• In November 2016, Merck Millipore collaborated with Evotec AG (Germany), to provide screening services for Merck’s collection of genetic reagents such as CRISPR and shRNA libraries. With Evotec’s screening expertise, Merck was able to explore and identify new drug targets.
• In August 2015, Becton, Dickinson and Company acquired Cellular Research, Inc. (U.S.), a biotechnology R&D company. Through this acquisition, BD combined its BD FACS single-cell sorting instrumentation and software with Cellular Research’s Precise assays based on the Molecular Indexing technology to offer customers an integrated workflow for measuring both nucleic acid and protein expression in cellular subtypes.

Critical questions the report answers:

• Where will all these developments take the industry in the long term?
• What are the upcoming trends for the HCS market?
• Which segment provides the most opportunity for growth?
• Who are the leading vendors operating in this market?
• What are the opportunities for new market entrants?

Request Sample Report:   https://www.marketsandmarkets.com/requestsampleNew.asp?id=42710391 

Increasing number of CROs providing HCS services

HCS is used in several stages of the drug discovery process, including primary and secondary screening, target identification and validation and toxicity studies. As HCS instruments are expensive, they add to the overall drug development expense for pharmaceutical and biopharmaceutical companies. Moreover, budgetary restrictions among academic institutes restrict the purchase of these instruments.

Regional Growth Analysis:

North America is the largest market for high-content screening, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. High R&D expenditure, the presence of major pharmaceutical market players, and increasing government support are some of the factors contributing to the large share of North America in the market. However, the Asia-Pacific market is expected to register the highest growth during the forecast period owing to increased research in drug discovery, government initiatives, growing focus of multinational companies on emerging markets, and developing R&D infrastructure.